Indian Generics File Fewer Patent Challenges In New Era
This article was originally published in PharmAsia News
Executive Summary
Indian drug makers are backing away from their tendency to challenge the patents of branded drugs in favor of taking a more cautious approach. As a result, the number of patent challenges filed in the United States by Indian pharmas in the past few years has declined by nearly half. The trend has been slowed in part because the owners of those patents have been taking steps to compete with the generics makers for specific drugs. As a result, Dr. Reddy's, Glenmark, Ranbaxy, Sun Pharma and Wockhardt are becoming more selective in their challenges. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.